Inhibrx Biosciences, Inc. (INBX)

In the past six months, Inhibrx Biosciences' stock price has been significantly impacted by positive clinical trial results, particularly for Ozekibart, leading to a 70% surge in October 2025. The stock reached multiple all-time highs, including $83.93 USD on October 31, 2025, $87.4 USD on November 24, 2025, and $93.51 on December 8, 2025. In December 2025, Inhibrx provided progress updates on its INBRX-106 program and the expansion cohorts of the ozekibart (INBRX-109) program. Citizens reiterated a "Market Perform" rating on the stock in November and December 2025, citing limited data disclosures. The company reported Q3 2025 earnings per share (EPS) of -$2.28, beating analysts' consensus estimates of -$2.94, and reported financial results for the third quarter of 2025 following the completion of the sale of INBRX-101. Overall, the stock has seen a substantial increase, with its price rising 298.43% over the last six months.

Traditional demand seasonality is not applicable to Inhibrx Biosciences, Inc., as its therapeutic candidates are still in clinical development and not yet commercially available. However, seasonal chart analysis suggests a historical "Buy Date of September 20 and a Sell Date of January 4," resulting in a geometric average return of 51.57% above the S&P 500 Total Return Index over the past four years, although this analysis is based on limited data.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates using its proprietary modular protein engineering platforms. The company operates within the Healthcare sector, specifically in the Biotechnology industry, creating therapeutics for life-threatening conditions like oncology, autoimmune diseases, and rare genetic disorders. Its clinical pipeline includes INBRX-109 (Ozekibart) for chondrosarcoma, colorectal cancer, and Ewing sarcoma, INBRX-106 for metastatic solid tumors, and INBRX-101 for alpha-1 antitrypsin deficiency (AATD). Positive topline results were reported for Ozekibart in chondrosarcoma in October 2025, and a registration-enabling trial for INBRX-101 was initiated in April 2023.

Inhibrx Biosciences, Inc. is headquartered in La Jolla, California, United States. The company's primary activities involve research, development, and the advancement of biologic candidates through regulated clinical pathways. Specific details regarding international operational facilities or a broad global market presence for its products are not explicitly detailed, as its clinical trials are ongoing, but their specific global reach is not specified.

Inhibrx Biosciences' brand reputation is closely linked to its scientific advancements and clinical trial outcomes, with positive influence from the promising results of Ozekibart (INBRX-109) in chondrosarcoma, leading to significant stock performance. The stock has outperformed the US Biotechs industry and the broader US Market over the past year. According to MarketBeat, Inhibrx Biosciences scored higher than 12% of companies evaluated and ranked 831st out of 876 stocks in the medical sector. No specific negative events unrelated to clinical trial outcomes or general market sentiment have been identified as significantly impacting its brand reputation in the past year.

Inhibrx Biosciences, Inc. has 182 institutional owners and shareholders, holding a total of 11,275,330 shares, with major shareholders including Viking Global Investors Lp, Perceptive Advisors Llc, and Sanofi. Individual insiders own 18.9% of the company's shares, totaling 2,753,354 shares, with Mark Lappe, the Founder, CEO & Chairman, directly owning 6.36% of the company's shares.